Modality
Nanobody
MOA
CFTRmod
Target
CD123
Pathway
Incretin
LGSPancreatic CaNASH
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Apr 2030
Phase 2Current
NCT07642259
583 pts·NASH
2020-03→2030-04·Active
NCT06585697
1,589 pts·LGS
2017-01→TBD·Terminated
2,172 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-254.1y awayPh2 Data· NASH
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Termina…
P2
Active
Catalysts
Ph2 Data
2030-04-25 · 4.1y away
NASH
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07642259 | Phase 2 | NASH | Active | 583 | ORR |
| NCT06585697 | Phase 2 | LGS | Terminated | 1589 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| DAW-8159 | Day One Bio | Phase 2 | PSMA | |
| Zorizumab | Beam | Approved | CD123 | |
| Niratinib | Alumis | NDA/BLA | TIM-3 | |
| Adagralucimab | Caribou Bio | NDA/BLA | CD123 |